References

1.

Aman MG, Findling RL, Hardan AY, et al. Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension. J Child Adolesc Psychopharmacol. 2016 Mar 15PMID: 26978327. [PMC free article: PMC5510039] [PubMed: 26978327]

2.

Aman M, Rettiganti M, Nagaraja HN, et al. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. J Child Adolesc Psychopharmacol 2015 Aug;25(6):482–93. PMID: 26262903. [PMC free article: PMC4545698] [PubMed: 26262903]

3.

Scahill L, Sukhodolsky DG, Anderberg E, et al. Sensitivity of the modified Children’s Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. Autism. 2015 Apr 16PMID: 25882391. [PubMed: 25882391]

4.

Scahill L, Hallett V, Aman MG, et al. Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 2013 Mar;43(3):739–46. PMID: 23104617. [PMC free article: PMC3886122] [PubMed: 23104617]

5.

Arnold LE, Farmer C, Kraemer HC, et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010 Apr;20(2):83–93. PMID: 20415603. [PMC free article: PMC2865212] [PubMed: 20415603]

6.

Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 2008 Jun;18(3):227–36. PMID: 18582177. [PMC free article: PMC2935828] [PubMed: 18582177]

7.

Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005 Dec;15(6):869–84. PMID: 16379507. [PubMed: 16379507]

8.

McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005 Jun;162(6):1142–8. PMID: 15930063. [PubMed: 15930063]

9.

Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004 Jun;161(6):1125–7. PMID: 15169706. [PubMed: 15169706]

10.

McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002 Aug 1;347(5):314–21. PMID: 12151468. [PubMed: 12151468]

11.

Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003 Dec;42(12):1443–50. PMID: 14627879. [PubMed: 14627879]

12.

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005 Jul;162(7):1361–9. PMID: 15994720. [PubMed: 15994720]

13.

Amatachaya A, Jensen MP, Patjanasoontorn N, et al. The short-term effects of transcranial direct current stimulation on electroencephalography in children with autism: a randomized crossover controlled trial. Behav Neurol 2015;2015:928631. PMID: 25861158. [PMC free article: PMC4377433] [PubMed: 25861158]

14.

Amatachaya A, Auvichayapat N, Patjanasoontorn N, et al. Effect of anodal transcranial direct current stimulation on autism: a randomized double-blind crossover trial. Behav Neurol 2014;2014:173073. PMID: 25530675. [PMC free article: PMC4230001] [PubMed: 25530675]

15.

Arnold LE, Aman MG, Hollway J, et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. J Child Adolesc Psychopharmacol 2012 Jun;22(3):198–205. PMID: 22537359. [PMC free article: PMC3417385] [PubMed: 22537359]

16.

Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010 Feb 1;34(1):32–6. PMID: 19772883. [PubMed: 19772883]

17.

Akhondzadeh S, Tajdar H, Mohammadi MR, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 2008 Sep;39(3):237–45. PMID: 17929164. [PubMed: 17929164]

18.

Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006 Oct;45(10):1196–205. PMID: 17003665. [PubMed: 17003665]

19.

Al-Ayadhi LY, Elamin NE. Camel Milk as a Potential Therapy as an Antioxidant in Autism Spectrum Disorder (ASD). Evid Based Complement Alternat Med 2013;2013:602834. PMID: 24069051. [PMC free article: PMC3773435] [PubMed: 24069051]

20.

Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013 Jan;225(1):51–9. PMID: 22782459. [PubMed: 22782459]

21.

Bent S, Hendren RL, Zandi T, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry 2014 Jun;53(6):658–66. PMID: 24839884. [PMC free article: PMC4076340] [PubMed: 24839884]

22.

Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 2011 May;41(5):545–54. PMID: 20683766. [PMC free article: PMC3076562] [PubMed: 20683766]

23.

Bertoglio K, Jill James S, Deprey L, et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med 2010 May;16(5):555–60. PMID: 20804367. [PubMed: 20804367]

24.

Chugani DC, Chugani HT, Wiznitzer M, et al. Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. J Pediatr 2016 Mar;170:45–53.e1–4. PMID: 26746121. [PubMed: 26746121]

25.

Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012 Dec;21(6):700–9. PMID: 22616853. [PubMed: 22616853]

26.

Chez MG, Buchanan TM, Becker M, et al. Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology 2003 Oct–Dec;1(2):83–8.

27.

Dean OM, Gray KM, Villagonzalo KA, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. 2016 Jun 17PMID: 27316706. [PubMed: 27316706]

28.

Dadds MR, MacDonald E, Cauchi A, et al. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord 2014 Mar;44(3):521–31. PMID: 23888359. [PubMed: 23888359]

29.

Duffy FH, Shankardass A, McAnulty GB, et al. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol 2014;14:70. PMID: 24885033. [PMC free article: PMC4022403] [PubMed: 24885033]

30.

Findling RL, Mankoski R, Timko K, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry 2014 Jan;75(1):22–30. PMID: 24502859. [PubMed: 24502859]

31.

Fahmy SF, El-hamamsy MH, Zaki OK, et al. L-Carnitine supplementation improves the behavioral symptoms in autistic children. Research in Autism Spectrum Disorders 2013;7(1):159–66. 2012-29769-018.

32.

Ghaleiha A, Alikhani R, Kazemi MR, et al. Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. J Child Adolesc Psychopharmacol. 2016 Apr 29PMID: 27128958. [PubMed: 27128958]

33.

Ghalichi F, Ghaemmaghami J, Malek A, et al. Effect of gluten free diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a randomized clinical trial. World J Pediatr. 2016 Jun 10PMID: 27286693. [PubMed: 27286693]

34.

Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev 2014;45(2):185–92. PMID: 23801256. [PubMed: 23801256]

35.

Geier DA, Kern JK, Davis G, et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit. 2011 Jun;17(6):Pi15–23. PMID: 21629200. [PMC free article: PMC3539542] [PubMed: 21629200]

36.

Granpeesheh D, Tarbox J, Dixon DR, et al. Randomized trial of hyperbaric oxygen therapy for children with autism. Research in Autism Spectrum Disorders 2010 April 2010/June;4(2):268–75. .

37.

Ghaleiha A, Rasa SM, Nikoo M, et al. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. Psychiatry Res 2015 Sep 30;229(1–2):181–7. PMID: 26208985. [PubMed: 26208985]

38.

Ghaleiha A, Mohammadi E, Mohammadi MR, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs 2013 Dec;15(6):505–14. PMID: 23821414. [PubMed: 23821414]

39.

Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2013 May;16(4):783–9. PMID: 22999292. [PubMed: 22999292]

40.

Ghaleiha A, Ghyasvand M, Mohammadi MR, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. J Psychopharmacol 2013 Oct 15;28(7):677–85. PMID: 24132248. [PubMed: 24132248]

41.

Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatr Neurol 2015 Jan;52(1):77–81. PMID: 25451017. [PubMed: 25451017]

42.

Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry 2013;13:196. PMID: 23886027. [PMC free article: PMC3737121] [PubMed: 23886027]

43.

Hendren RL, James SJ, Widjaja F, et al. Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism. J Child Adolesc Psychopharmacol. 2016 Feb 18PMID: 26889605. [PubMed: 26889605]

44.

Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2015 Nov;54(11):905–15. PMID: 26506581. [PMC free article: PMC4625086] [PubMed: 26506581]

45.

Smith T, Aman MG, Arnold LE, et al. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. J Am Acad Child Adolesc Psychiatry 2016 Oct;55(10):868–76.e2. PMID: 27663942. [PMC free article: PMC5108566] [PubMed: 27663942]

46.

Hyman SL, Stewart PA, Foley J, et al. The Gluten-Free/Casein-Free Diet: A Double-Blind Challenge Trial in Children with Autism. J Autism Dev Disord. 2015 Sep 5PMID: 26343026. [PubMed: 26343026]

47.

Handen BL, Johnson CR, McAuliffe-Bellin S, et al. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. J Child Adolesc Psychopharmacol 2011 Feb;21(1):43–50. PMID: 21309696. [PMC free article: PMC3037196] [PubMed: 21309696]

48.

Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010 Mar;35(4):990–8. PMID: 20010551. [PMC free article: PMC2846602] [PubMed: 20010551]

49.

Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012 Jun 1;71(11):956–61. PMID: 22342106. [PMC free article: PMC4914359] [PubMed: 22342106]

50.

Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev 2012 Oct;43(5):674–82. PMID: 22392415. [PubMed: 22392415]

51.

Harrison Elder J, Shankar M, Shuster J, et al. The Gluten-Free, Casein-Free Diet In Autism: Results of A Preliminary Double Blind Clinical Trial. Journal of Autism and Developmental Disorders 2006 Apr;36(3):413–20. PMID: 2006-07517-011. [PubMed: 16555138]

52.

Seung H, Rogalski Y, Shankar M, et al. The gluten- and casein-free diet and autism: Communication outcomes from a preliminary double-blind clinical trial. Journal of Medical Speech-Language Pathology 2007 Dec;15(4):337–45.

53.

Johnson CR, Handen BL, Zimmer M, et al. Effects of gluten free / casein free diet in young children with autism: A pilot study. Journal of Developmental and Physical Disabilities 2011 2015-12-09;23(3):213–25. 2011-08445-004.

54.

King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001 Jun;40(6):658–65. PMID: 11392343. [PubMed: 11392343]

55.

Kent JM, Kushner S, Ning X, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 2013 Aug;43(8):1773–83. PMID: 23212807. [PubMed: 23212807]

56.

Kent JM, Hough D, Singh J, et al. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2013 Dec;23(10):676–86. PMID: 24350813. [PMC free article: PMC3870601] [PubMed: 24350813]

57.

King BH, Dukes K, Donnelly CL, et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr 2013 Nov;167(11):1045–52. PMID: 24061784. [PMC free article: PMC4913472] [PubMed: 24061784]

58.

King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009 Jun;66(6):583–90. PMID: 19487623. [PMC free article: PMC4112556] [PubMed: 19487623]

59.

Klaiman C, Huffman L, Masaki L, et al. Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2013 Jun;23(5):320–8. PMID: 23782126. [PubMed: 23782126]

60.

Lamberti M, Siracusano R, Italiano D, et al. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. Paediatr Drugs 2016 Aug;18(4):319–29. PMID: 27278054. [PubMed: 27278054]

61.

Lv YT, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 2013;11:196. PMID: 23978163. [PMC free article: PMC3765833] [PubMed: 23978163]

62.

Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e202. PMID: 23233021. [PMC free article: PMC3565189] [PubMed: 23233021]

63.

Mankad D, Dupuis A, Smile S, et al. A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 2015;6:18. PMID: 25798215. [PMC free article: PMC4367852] [PubMed: 25798215]

64.

McCracken JT, Badashova KK, Posey DJ, et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 2014 Jun;14(3):295–302. PMID: 23856854. [PMC free article: PMC4034115] [PubMed: 23856854]

65.

Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007 Feb 15;61(4):538–44. PMID: 17276750. [PubMed: 17276750]

66.

Jahromi LB, Kasari CL, McCracken JT, et al. Positive Effects of Methylphenidate on Social Communication and Self-Regulation in Children with Pervasive Developmental Disorders and Hyperactivity. Journal of Autism and Developmental Disorders 2009 Mar;39(3):395–404. PMID: [PMC free article: PMC4374624] [PubMed: 18752063]

67.

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005 Nov;62(11):1266–74. PMID: 16275814. [PubMed: 16275814]

68.

Mohammadi MR, Yadegari N, Hassanzadeh E, et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clin Neuropharmacol. 2013 Nov–Dec;36(6):179–84. PMID: 24201232. [PubMed: 24201232]

69.

Marcus RN, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 2011 Jun;21(3):229–36. PMID: 21663425. [PubMed: 21663425]

70.

Aman MG, Kasper W, Manos G, et al. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol 2010 Oct;20(5):415–22. PMID: 20973712. [PubMed: 20973712]

71.

Varni JW, Handen BL, Corey-Lisle PK, et al. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther 2012 Apr;34(4):980–92. PMID: 22444782. [PubMed: 22444782]

72.

Amoros E, Tzvetkovitch A. [Aquatic therapy for children with autism]. Soins Pediatr Pueric 2014 Jan–Feb(276):29–30. PMID: 24617090. [PubMed: 24617090]

73.

Robb AS, Andersson C, Bellocchio EE, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6–17 years old):results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord 2011;13(1)PMID: 21731831. [PMC free article: PMC3121213] [PubMed: 21731831]

74.

Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009 Nov;48(11):1110–9. PMID: 19797985. [PubMed: 19797985]

75.

Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009 Dec;124(6):1533–40. PMID: 19948625. [PubMed: 19948625]

76.

Munasinghe SA, Oliff C, Finn J, et al. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. J Autism Dev Disord 2010 Sep;40(9):1131–8. PMID: 20204691. [PubMed: 20204691]

77.

Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008 Feb;17(1):1–8. PMID: 18080171. [PubMed: 18080171]

78.

Nikvarz N, Alaghband-Rad J, Tehrani-Doost M, et al. Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder. Pharmacopsychiatry 2016 Jun 14PMID: 27299475. [PubMed: 27299475]

79.

Navarro F, Pearson DA, Fatheree N, et al. Are ‘leaky gut’ and behavior associated with gluten and dairy containing diet in children with autism spectrum disorders? Nutr Neurosci 2015 May;18(4):177–85. PMID: 24564346. [PubMed: 24564346]

80.

Nikoo M, Radnia H, Farokhnia M, et al. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015 Jan–Feb;38(1):11–7. PMID: 25580916. [PubMed: 25580916]

81.

Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006 Jun;21(6):450–5. PMID: 16948927. [PubMed: 16948927]

82.

Pusponegoro HD, Ismael S, Firmansyah A, et al. Gluten and casein supplementation does not increase symptoms in children with autism spectrum disorder. Acta Paediatr 2015 Nov;104(11):e500–e5. PMID: 26148018. [PubMed: 26148018]

83.

Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol 2013 Jun;23(5):337–51. PMID: 23782128. [PMC free article: PMC3689935] [PubMed: 23782128]

84.

Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010 Oct 1;34(7):1269–72. PMID: 20637249. [PubMed: 20637249]

85.

Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr 2009;9:21. PMID: 19284641. [PMC free article: PMC2662857] [PubMed: 19284641]

86.

Sun C, Zou M, Zhao D, et al. Efficacy of Folic Acid Supplementation in Autistic Children Participating in Structured Teaching: An Open-Label Trial. Nutrients 2016;8(6)PMID: 27338456. [PMC free article: PMC4924178] [PubMed: 27338456]

87.

Sampanthavivat M, Singkhwa W, Chaiyakul T, et al. Hyperbaric oxygen in the treatment of childhood autism: a randomised controlled trial. Diving Hyperb Med 2012 Sep;42(3):128–33. PMID: 22987458. [PubMed: 22987458]

88.

Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004 Nov;114(5):e634–41. PMID: 15492353. [PubMed: 15492353]

89.

Pandina GJ, Bossie CA, Youssef E, et al. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007 Feb;37(2):367–73. PMID: 17019624. [PubMed: 17019624]

90.

Saad K, Eltayeb AA, Mohamad IL, et al. A Randomized, Placebo-controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders. Clin Psychopharmacol Neurosci 2015 Aug 31;13(2):188–93. PMID: 26243847. [PMC free article: PMC4540030] [PubMed: 26243847]

91.

Scahill L, McCracken JT, King BH, et al. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Am J Psychiatry. 2015 Aug 28:appiajp201515010055. PMID: 26315981. [PubMed: 26315981]

92.

Du L, Shan L, Wang B, et al. A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism. J Child Adolesc Psychopharmacol 2015 Sep;25(7):585–8. PMID: 26258842. [PubMed: 26258842]

93.

Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005 Nov;44(11):1137–44. PMID: 16239862. [PubMed: 16239862]

94.

Voigt RG, Mellon MW, Katusic SK, et al. Dietary docosahexaenoic acid supplementation in children with autism. J Pediatr Gastroenterol Nutr 2014 Jun;58(6):715–22. PMID: 24345834. [PubMed: 24345834]

95.

van der Meer JM, Harfterkamp M, van de Loo-Neus G, et al. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms. J Clin Psychopharmacol 2013 Dec;33(6):824–7. PMID: 24018545. [PubMed: 24018545]

96.

Harfterkamp M, Buitelaar JK, Minderaa RB, et al. Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. J Child Adolesc Psychopharmacol 2014 Nov;24(9):481–5. PMID: 25369243. [PubMed: 25369243]

97.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012 Jul;51(7):733–41. PMID: 22721596. [PubMed: 22721596]

98.

Harfterkamp M, Buitelaar JK, Minderaa RB, et al. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol 2013 Apr;23(3):194–9. PMID: 23578015. [PubMed: 23578015]

99.

Wink LK, Early M, Schaefer T, et al. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol 2014 Mar;24(2):78–82. PMID: 24564519. [PMC free article: PMC5248544] [PubMed: 24564519]

100.

Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011 Feb;41(2):175–84. PMID: 20535539. [PubMed: 20535539]

101.

Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci 2010 Apr;13(2):87–100. PMID: 20406576. [PubMed: 20406576]

102.

Pedersen L, Parlar S, Kvist K, et al. Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders: behavioural and psychometric measures of dietary response. Nutr Neurosci 2014 Sep;17(5):207–13. PMID: 24075141. [PubMed: 24075141]

103.

Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006 Nov;21(6):363–7. PMID: 17012983. [PubMed: 17012983]

104.

Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005 Oct;25(5):485–9. PMID: 16160627. [PubMed: 16160627]

105.

Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002 Sep;5(4):251–61. PMID: 12168688. [PubMed: 12168688]